| Literature DB >> 35323016 |
Omar Hamza Bin Manjur1, Mokibul Hassan Afrad2, Manjur Hossain Khan3, Mohabbat Hossain1, Zannat Kawser1, Ahmed Nawsher Alam3, Nandita Banik3, Saruar Alam1, Mallick Masum Billah3, Nawroz Afreen3, Farhana Khanam2, Taufiqur Rahman Bhuiyan2, Mohammed Ziaur Rahman2, Emilie Westeel4, Jean-Luc Berland4, Florence Komurian-Pradel4, Sayera Banu2, Mustafizur Rahman2, Nicholas R Thompson5,6, Firdausi Qadri3, Tahmina Shirin3.
Abstract
We report the coding-complete genome sequences of 25 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sublineage B.1.1.529 Omicron strains obtained from Bangladeshi individuals in samples collected between December 2021 and January 2022. Genomic data were generated by Nanopore sequencing using the amplicon sequencing approach developed by the ARTIC Network.Entities:
Year: 2022 PMID: 35323016 PMCID: PMC9022525 DOI: 10.1128/mra.00119-22
Source DB: PubMed Journal: Microbiol Resour Announc ISSN: 2576-098X
Data for Bangladesh SARS-CoV-2 Sublineage B.1.1.529 isolates
| Sample | Date of sample collection (day/mo/yr) | Patient age (yr) | Sex | Symptom(s) | Name of vaccine received | Travel history | Pangolin lineage | Genome size (bp) | Coverage (%) | GC content (%) | SRA accession no. | GenBank accession no. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OIS-0630 | 6/12/2021 | 31 | F | + | AstraZeneca | Zimbabwe | B.1.1.529.1 | 29,743 | 99.5 | 40.7 |
|
|
| OIS-0631 | 6/12/2021 | 21 | F | + | AstraZeneca | Zimbabwe | B.1.1.529.1 | 29,743 | 99.5 | 42.3 |
|
|
| OIS-0633 | 8/12/2021 | 47 | F | − | AstraZeneca + Pfizer-BioNTech (booster dose) | Egypt | B.1.1.529.1 | 29,740 | 99.5 | 40.2 |
|
|
| OIS-0648 | 14/12/2021 | 18 | F | + | NA | United Kingdom | B.1.1.529.1 | 29,743 | 99.5 | 41.40 |
|
|
| OIS-0634 | 19/12/2021 | 30 | F | − | AstraZeneca | B.1.1.529.1 | 29,740 | 99.5 | 41.30 |
|
| |
| OIS-0637 | 19/12/2021 | 84 | M | + | Moderna | B.1.1.529.1 | 29,743 | 99.5 | 40.10 |
|
| |
| OIS-0649 | 22/12/2021 | 23 | F | + | Pfizer-BioNTech | United Kingdom | B.1.1.529.1 | 29,743 | 99.5 | 40.60 |
|
|
| IR-1955 | 23/12/2021 | 56 | M | + | Pfizer-BioNTech | Denmark | B.1.1.529.1 | 29,743 | 99.5 | 41.10 |
|
|
| OIS-0664 | 26/12/2021 | 65 | M | NA | Pfizer-BioNTech | B.1.1.529.1 | 29,743 | 99.5 | 40.70 |
|
| |
| OIS-0666 | 26/12/2021 | 53 | F | NA | NA | B.1.1.529.1 | 29,743 | 99.5 | 40.00 |
|
| |
| IR-1979 | 27/12/2021 | 49 | F | + | Pfizer-BioNTech | Denmark | B.1.1.529.1 | 29,743 | 99.5 | 40.30 |
|
|
| IR-1982 | 27/12/2021 | 65 | M | + | AstraZeneca | B.1.1.529.1 | 29,743 | 99.5 | 40.40 |
|
| |
| IR-1983 | 27/12/2021 | 65 | F | + | AstraZeneca | B.1.1.529.1 | 29,743 | 99.5 | 42.10 |
|
| |
| TND-07-0639 | 28/12/2021 | 35 | F | + | Sinopharm | B.1.1.529.1 | 29,743 | 99.5 | 40.80 |
|
| |
| OIS-686 | 30/12/2021 | 61 | M | + | AstraZeneca | B.1.1.529.1 | 29,743 | 99.5 | 40.70 |
|
| |
| TND-04-0674 | 2/1/2022 | 64 | M | NA | AstraZeneca | B.1.1.529.1 | 29,743 | 99.5 | 41.60 |
|
| |
| TND-04-0675 | 2/1/2022 | 29 | F | + | Pfizer-BioNTech | Germany | B.1.1.529.1 | 29,743 | 99.5 | 40.40 |
|
|
| OIS-688 | 3/1/2022 | 48 | F | NA | NA | B.1.1.529.1 | 29,743 | 99.5 | 40.10 |
|
| |
| IR-2027 | 3/1/2022 | 35 | F | + | AstraZeneca | UAE | B.1.1.529.1 | 29,743 | 99.5 | 40.80 |
|
|
| TND-09-0338 | 6/1/2022 | 49 | M | + | AstraZeneca | B.1.1.529.2 | 29,729 | 99.5 | 41.10 |
|
| |
| TND-05-0426 | 8/1/2022 | 60 | M | + | Sinopharm | B.1.1.529.2 | 29,729 | 99.5 | 40.30 |
|
| |
| TND-04-0735 | 9/1/2022 | 19 | M | + | Sinopharm | B.1.1.529.2 | 29,729 | 99.5 | 40.20 |
|
| |
| TND-04-0736 | 9/1/2022 | 43 | M | + | Sinopharm | B.1.1.529.2 | 29,729 | 99.5 | 40.50 |
|
| |
| TND-04-0747 | 10/1/2022 | 32 | M | + | AstraZeneca | B.1.1.529.2 | 29,714 | 99.5 | 40.90 |
|
| |
| TND-04-0748 | 10/1/2022 | 45 | M | + | Sinopharm | B.1.1.529.2 | 29,729 | 99.5 | 41.10 |
|
|
F, female; M, male.
+, present (fever, cough, or mild weakness); −, absent; NA, information not available.
With reference to the Wuhan Hu-1 genome (GenBank accession number NC_045512.2).